FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$2.505

Market cap

$291.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$319.15M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 38

Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform ...

Highlights
FATE's EPS is up by 27% year-on-year and by 5% since the previous quarter
The net income has grown by 26% YoY and by 4.7% from the previous quarter
The gross profit has dropped by 53% year-on-year and by 5% since the previous quarter
FATE's revenue has dropped by 53% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT PTCT BDX NBIX

Key stats

What are the main financial stats of FATE

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
2.24%
1 week
3.09%
1 month
-14.21%
1 year
134.11%
YTD
154.94%
QTD
-7.22%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$6.32M
Gross profit
$6.32M
Operating income
-$139.42M
Net income
-$129.91M
Gross margin
100%
Net margin
-2,056.8%
The net margin has dropped by 56% year-on-year
The gross profit has dropped by 53% year-on-year and by 5% since the previous quarter
FATE's revenue has dropped by 53% year-on-year and by 5% since the previous quarter
The operating margin has contracted by 47% YoY

Price vs fundamentals

How does FATE's price correlate with its fundamentals

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.62
P/S
47.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
50.53
FATE's EPS is up by 27% year-on-year and by 5% since the previous quarter
FATE's price to book (P/B) is 165% higher than its last 4 quarters average of 0.6 but 31% lower than its 5-year quarterly average of 2.3
The company's equity fell by 38% YoY and by 13% QoQ
The stock's price to sales (P/S) is 141% more than its last 4 quarters average of 19.3 and 41% more than its 5-year quarterly average of 33.1
FATE's revenue has dropped by 53% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales has dropped by 56% year-on-year
The ROE has contracted by 14% YoY and by 7% from the previous quarter
The ROIC has contracted by 7% YoY and by 3.9% from the previous quarter
Fate Therapeutics's return on assets has decreased by 4.2% YoY and by 3.4% QoQ

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is 171% greater than its total liabilities
FATE's current ratio is down by 34% YoY
The company's quick ratio fell by 33% YoY
The debt is 57% smaller than the equity
The company's debt to equity rose by 48% YoY and by 13% QoQ
The company's equity fell by 38% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.